Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Quest Diagnostics Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $17.99, while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | DGX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $238.50 |
52-Week Low | $17.80 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.20, up 0.72% with a bearish technical outlook indicated by moving averages. The ETF generates weekly dividend distributions but faces significant price depreciation concerns highlighted in recent financial media coverage. Current RSI levels suggest potential oversold conditions while the stock tests key support at $18.
The outlook remains challenging with negative sentiment surrounding the ETF's strategy and performance. While high dividend yields attract income investors, the underlying price erosion presents substantial risk. Analyst commentary questions the sustainability of returns amid ongoing capital depreciation.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
